Caplin Point Laboratories Q4 Results
- BSE: 524742
- NSE: CAPLIPOINT
- ISIN: INE475E01026
- Sector: Biotechnology & Drugs
BSE
2,603.40
-17.00 (-0.65%)
-17.00 (-0.65%)Volume5.83 K
Updated: Fri 10 Jul, 2026 | 15:29:15
NSE
2,583.60-37.80 (-1.44%)
-37.80 (-1.44%)Volume1.32 L
Updated: Fri 10 Jul, 2026 | 15:41:53
Technical Trends
Long TermConsiders price movement over the last 6 months
Not Available
Short TermConsiders price movement over the last 1-2 weeks
Not Available
- Bearish
- Moderately Bearish
- Neutral
- Moderately Bullish
- Bullish
Insight: Trends unavailable at the moment.
Q4 Results Highlights
- Total Income₹600.16 Cr.(19.45%)
- Operating Profit₹185.44 Cr.(22.79%)
- Profit After Tax₹170.11 Cr.(19.32%)
- Operating Margin30.90%(2.80%)
Note: Comparison is on YoY basis
Quarterly - Caplin Point Laboratories Q4 Results
*All figures in crores except per share values
| Fiscal Period | Mar 26 | Dec 25 | QoQ Comp | Mar 24 | YoY Comp |
|---|---|---|---|---|---|
| Total Operating Expense | 414.72 | 372.36 | 11.38% | 324.39 | 18.01% |
| Depreciation/ Amortization | 18.80 | 19.28 | -2.49% | 16.40 | 10.33% |
| Operating Income | 185.44 | 170.41 | 8.82% | 128.83 | 22.79% |
| Net Income | 170.11 | 163.88 | 3.80% | 121.59 | 19.32% |
| Other Operating Expenses Total | 98.30 | 88.16 | 11.50% | 6.13 | 883.00% |
| Net Income Before Taxes | 213.44 | 203.89 | 4.68% | 146.03 | 20.81% |
| Total Revenue | 600.16 | 542.77 | 10.57% | 453.22 | 19.45% |
| Selling/ General/ Admin Expenses Total | 52.62 | 49.78 | 5.71% | 36.77 | 13.14% |
| Diluted Normalized EPS | 22.31 | 21.51 | 3.72% | 15.90 | 19.29% |
EQUITY QUICK LINKS
FROM MARKETS
Trending Stocks
✕
Wait for it…
Oops! Looks like you have exceeded the limit to bookmark the image. Remove some to bookmark this image.